Business
VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting
Presentations will highlight positive preclinical and Phase 1b data of novel BET inhibitor, VYN201, in nonsegmental vitiligo BRIDGEWATER, N.J., May 01, 2024
About this update from Vyne Therapeutics Inc.
[{"type":"text","content":"Presentations will highlight positive preclinical and Phase 1b data of novel BET inhibitor, VYN201, in nonsegmental vitiligo BRIDGEWATER, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced two abstracts reporting results for its novel BET inhibitor, VYN201, have been selected for presentation at the 81st Annual Meeting of the Society for Investigative Dermatology (SID), being held May 15-18, 2024 in Dallas, TX, USA. “We look forward to sharing our preclinical and Phase 1b data for VYN201 with researchers and clinicians at the upcoming SID Annual Meeting,” said Iain Stuart, Ph.D., Chief Scientific Officer of VYNE. “Our data support the advancement of VYN201 as a differentiated therapy for the potential treatment of nonsegmental vitiligo.” Presentation Details: 1.Title:Preclinical studies: Translational evaluation of VYN201, a pan-BD BET inhibitor, for the treatment of non-segmental vitiligo Final ID Number:LB1055 Session:Select E-Poster Discussions (Session 1): Late Breaking Abstracts Session Category:Translational Studies and Early Preclinical to Clinical Presenter:Dr. Iain Stuart Session Date/Time:Thursday, May 16, 2024, 5:00-6:30 p.m. CDT Location:Trinity Exhibit Hall, Stage 52.Title:Phase 1b: Translational evaluation of VYN201, a pan-BD BET inhibitor, for the treatment of non-segmental vitiligo Final ID Number:LB1056 Session:Concurrent Mini-Symposium 18: Late Breaking Abstracts Session Category:Translational Studies and Early Preclinical to Clinical Presenter:Dr. Iain Stuart Session Date/Time:Saturday, May 18, 2024, 10:00 a.m.-12:30 p.m. CDT Location:Cortez C/D About VitiligoVitiligo is a chronic autoimmune depigmenting disorder of the skin, characterized by the loss of pigment producing cells known as melanocytes. Vitiligo is the most common depigmenting skin condition, with a prevalence estimated at 0.5-2.0% of the world population.1 There is currently only one FDA-approved product for the treatment of vitiligo. Nonsegmental vitiligo is the most common type of vitiligo. About VYN201 VYN201 is a pan-bromodomain BET inhibitor designed to be locally administered as a “soft” drug to address diseases inv...